BioAtla (BCAB) Free Cash Flow (2020 - 2026)
BioAtla's (BCAB) quarterly Free Cash Flow came in at -$419000.0 in Q2 2026, up 97.03% on a YoY basis from -$212655.2 in Q2 2025, and up 92.04% quarter-over-quarter from -$5.3 million in Q1 2026.
Powered by 
Analysis
BioAtla (BCAB) Free Cash Flow (2020 - 2026) Analysis & Trends
BioAtla (BCAB) has reported Free Cash Flow for 7 consecutive years, with -$419000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Free Cash Flow rose 97.03% year-over-year to -$419000.0; the trailing twelve-month figure through Jun 2026 stood at -$23.5 million (up 55.12% YoY), and the FY2025 full-year result was -$48.2 million, up 32.99% from the prior year.
- Free Cash Flow advanced to -$419000.0 in Q2 2026 per BCAB's latest filing, from -$5.3 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$419000.0 in Q2 2026 and bottomed at -$30.8 million in Q1 2024.
- Historically, Free Cash Flow has averaged -$17.8 million across 5 years, with a median of -$18.1 million in 2022.
- The sharpest annual moves came in 2025 and 2026: Free Cash Flow sank 92.54% in 2025, then soared 97.03% in 2026.
- Over 5 years, Free Cash Flow stood at -$24.4 million in 2022, then declined by 22.77% to -$29.9 million in 2023, then soared by 43.93% to -$16.8 million in 2024, then soared by 52.84% to -$7.9 million in 2025, then jumped by 94.71% to -$419000.0 in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$419000.0, -$5.3 million, and -$7.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 3.49 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 3.43 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.01 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 572.80 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -563.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 408.00 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -95.09 Mn |
| 10 | BioAtla | 2.33 Mn | 2.33 Mn | - | -419,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -419,000.00 |
| Mar 31, 2026 | -5.27 Mn |
| Dec 31, 2025 | -7.92 Mn |
| Sep 30, 2025 | -9.88 Mn |
| Jun 30, 2025 | -14.12 Mn |
| Mar 31, 2025 | -16.29 Mn |
| Dec 31, 2024 | -16.78 Mn |
| Sep 30, 2024 | -5.13 Mn |
| Jun 30, 2024 | -19.19 Mn |
| Mar 31, 2024 | -30.83 Mn |
| Dec 31, 2023 | -29.93 Mn |
| Sep 30, 2023 | -27.37 Mn |
| Jun 30, 2023 | -24.11 Mn |
| Mar 31, 2023 | -22.70 Mn |
| Dec 31, 2022 | -24.38 Mn |
| Sep 30, 2022 | -24.07 Mn |
| Jun 30, 2022 | -17.08 Mn |
| Mar 31, 2022 | -25.16 Mn |
| Dec 31, 2021 | -21.04 Mn |
| Sep 30, 2021 | -12.83 Mn |